Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec 1;105(12):3842-3853.
doi: 10.1210/clinem/dgaa575.

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Marieke de Vries  1 , Jan Westerink  1 , Karin H A H Kaasjager  1 , Harold W de Valk  1
Affiliations
Free PMC article
Meta-Analysis

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Marieke de Vries et al. J Clin Endocrinol Metab. .
Free PMC article

Abstract

Context: Nonalcoholic fatty liver disease (NAFLD) prevalence is high, especially in patients with obesity and type 2 diabetes, and is expected to rise steeply in the coming decades.

Objective: We estimated NAFLD prevalence in patients with type 1 diabetes and explored associated characteristics and outcomes.

Data sources: We reviewed PubMed and Embase for studies on NAFLD and type 1 diabetes to March 2020. We screened references of included articles.

Study selection: Two authors independently screened titles/abstracts. One author screened full text articles. NAFLD was defined as described in the individual studies: steatosis and/or fibrosis. Studies not reporting alternative causes of hepatic steatosis or defining NAFLD only as elevated liver enzymes, were excluded. Initially, 919 articles met the selection criteria.

Data extraction: One researcher performed data extraction and risk of bias assessment using standardized tables.

Data synthesis: We assessed pooled prevalence rates by meta-analysis using a random-effects model, subsequently exploring heterogeneity by subgroup-, meta-regression-, and sensitivity analysis. Twenty studies between 2009 and 2019 were included (n = 3901). Pooled NAFLD prevalence was 19.3% (95% CI, 12.3%-27.5%), increasing to 22.0% (95% CI, 13.9%-31.2%) in adults only. Pooled prevalence of ultrasound studies was high (27.1%, 95% CI, 18.7%-36.3%) compared to studies using magnetic resonance imaging (8.6%, 95% CI, 2.1%-18.6%), liver biopsy (19.3%, 95% CI, 10.0%-30.7%), or transient elastography (2.3%, 95% CI, 0.6%-4.8%).

Conclusion: NAFLD prevalence in patients with type 1 diabetes is considerable and is highly dependent on the specific diagnostic modality and NAFLD definition used. These data are helpful in directing actions to standardize NAFLD diagnosis, which will help defining contributing mechanisms and outcomes.

Keywords: DM1; NAFLD; NASH; fibrosis; nonalcoholic fatty liver disease; type 1 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study flowchart, date of search: March 20, 2020.
Figure 2.
Figure 2.
Forest plot overall NAFLD prevalence in patients with type 1 diabetes. NAFLD+, patients with nonalcoholic fatty liver disease; T1DM, type 1 diabetes mellitus.
Figure 3.
Figure 3.
Forest plot NAFLD prevalence in patients with type 1 diabetes, subgroups according to age-group: (1) adults, (2) children/adolescents. NAFLD+, patients with nonalcoholic fatty liver disease; T1DM, type 1 diabetes mellitus.
Figure 4.
Figure 4.
Forest plot NAFLD prevalence in patients with type 1 diabetes, subgroups according to diagnostic modality: (1) ultrasound, (2) MRI, (3) biopsy, (4) combination non-invasive risk score and TE. NAFLD+, patients with nonalcoholic fatty liver disease; T1DM, type 1 diabetes mellitus; MRI, magnetic resonance imaging; TE, transient elastography.
Figure 5.
Figure 5.
Forest plot NAFLD prevalence in patients with type 1 diabetes, subgroups according to NAFLD definition: (1) steatosis and fibrosis, (2) steatosis, (3) NAFLD, (4) LFC, (5) fibrosis. NAFLD+, patients with nonalcoholic fatty liver disease; T1DM, type 1 diabetes mellitus; LFC, liver fat content.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65-90. - PMC - PubMed
    1. Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169(9):ITC65-ITC80. - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. - PubMed
    1. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-1586. - PubMed
    1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. - PMC - PubMed

MeSH terms